Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo (USP), Brazil.
University of Glasgow, Institute of Cardiovascular & Medical Sciences.
J Hypertens. 2024 Jun 1;42(6):984-999. doi: 10.1097/HJH.0000000000003677. Epub 2024 Mar 1.
Nox1 signaling is a causal key element in arterial hypertension. Recently, we identified protein disulfide isomerase A1 (PDI) as a novel regulatory protein that regulates Nox1 signaling in VSMCs. Spontaneously hypertensive rats (SHR) have increased levels of PDI in mesenteric resistance arteries compared with Wistar controls; however, its consequences remain unclear. Herein, we investigated the role of PDI in mediating Nox1 transcriptional upregulation and its effects on vascular dysfunction in hypertension. We demonstrate that PDI contributes to the development of hypertension via enhanced transcriptional upregulation of Nox1 in vascular smooth muscle cells (VSMCs). We show for the first time that PDI sulfenylation by hydrogen peroxide contributes to EGFR activation in hypertension via increased shedding of epidermal growth factor-like ligands. PDI also increases intracellular calcium levels, and contractile responses induced by ANG II. PDI silencing or pharmacological inhibition in VSMCs significantly decreases EGFR activation and Nox1 transcription. Overexpression of PDI in VSMCs enhances ANG II-induced EGFR activation and ATF1 translocation to the nucleus. Mechanistically, PDI increases ATF1-induced Nox1 transcription and enhances the contractile responses to ANG II. Herein we show that ATF1 binding to Nox1 transcription putative regulatory regions is augmented by PDI. Altogether, we provide evidence that HB-EGF in SHR resistance vessels promotes the nuclear translocation of ATF1, under the control of PDI, and thereby induces Nox1 gene expression and increases vascular reactivity. Thus, PDI acts as a thiol redox-dependent enhancer of vascular dysfunction in hypertension and could represent a novel therapeutic target for the treatment of this disease.
Nox1 信号转导是动脉高血压的一个关键因素。最近,我们发现蛋白二硫键异构酶 A1(PDI)是一种新的调节蛋白,可调节 VSMCs 中的 Nox1 信号转导。与 Wistar 对照组相比,自发性高血压大鼠(SHR)肠系膜阻力动脉中 PDI 水平升高;然而,其后果尚不清楚。在此,我们研究了 PDI 在介导 Nox1 转录上调及其在高血压血管功能障碍中的作用。我们证明 PDI 通过增强血管平滑肌细胞(VSMCs)中 Nox1 的转录上调,促进高血压的发展。我们首次表明,过氧化氢介导的 PDI 亚磺酰化通过增加表皮生长因子样配体的脱落,促进高血压中 EGFR 的激活。PDI 还增加细胞内钙离子水平,并增加 ANG II 诱导的收缩反应。在 VSMCs 中沉默或药理学抑制 PDI 可显著降低 EGFR 激活和 Nox1 转录。在 VSMCs 中转染 PDI 可增强 ANG II 诱导的 EGFR 激活和 ATF1 向核内易位。从机制上讲,PDI 增加 ATF1 诱导的 Nox1 转录,并增强对 ANG II 的收缩反应。在此,我们证明 PDI 增强了 ATF1 与 Nox1 转录假定调节区的结合。总之,我们提供的证据表明,SHR 阻力血管中的 HB-EGF 促进了 ATF1 的核易位,受 PDI 的控制,从而诱导 Nox1 基因表达并增加血管反应性。因此,PDI 作为一种依赖硫醇氧化还原的高血压血管功能障碍增强剂,可能成为治疗这种疾病的新靶点。